Cargando…

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France

INTRODUCTION: Dulaglutide is a novel onceweekly administered glucagon-like peptide 1 receptor agonist (GLP-1 RA) for the management of type 2 diabetes mellitus (T2DM). The objective of this analysis was to estimate the cost-effectiveness of dulaglutide 1.5 mg versus exenatide QW for the management o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basson, Mickael, Ntais, Dionysios, Ayyub, Ruba, Wright, Donna, Lowin, Julia, Chartier, Florence, Roze, Stéphane, Norrbacka, Kirsi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801216/ https://www.ncbi.nlm.nih.gov/pubmed/29134607 http://dx.doi.org/10.1007/s13300-017-0321-0

Ejemplares similares

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

An indirect comparison of HbA(1c) treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
por: Martin, Alan A, et al.
Publicado: (2016)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

Barrier thickness dependence of Mg(x)Zn(1−x)O/ZnO quantum well (QW) on the performance of a p-NiO/QW/n-ZnO photodiode
por: Hwang, Jun Dar, et al.
Publicado: (2019)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
por: Brown, Emily, et al.
Publicado: (2021)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Technical specification for ultrahigh vacuum chambers for the antiproton accumulator wide quadrupoles (QW)
Publicado: (1979)

High potential application in bioremediation of selenate by Proteus hauseri strain QW4
por: Khalilian, Mohaddeseh, et al.
Publicado: (2015)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Photoluminescence and Band Alignment of Strained GaAsSb/GaAs QW Structures Grown by MBE on GaAs
por: Sadofyev, Yuri G., et al.
Publicado: (2010)

A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer
por: Wang, Jinhua, et al.
Publicado: (2019)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
por: Alatorre, Carlos, et al.
Publicado: (2017)

Improving the internal quantum efficiency of QD/QW hybrid structures by increasing the GaN barrier thickness
por: Jia, Zhigang, et al.
Publicado: (2020)

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
por: Zimner Rapuch, Sarah, et al.
Publicado: (2021)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

First Complete Genome Sequence of a Genogroup II Genotype 18 Porcine Norovirus, Strain QW125
por: Oka, Tomoichiro, et al.
Publicado: (2013)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
por: Bonora, Enzo, et al.
Publicado: (2021)

Mode of administration of dulaglutide: implications for treatment adherence
por: Amblee, Ambika
Publicado: (2016)

Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
por: Wang, Rijun, et al.
Publicado: (2021)

Exacerbation of atrial fibrillation related to dulaglutide use
por: Lee, Jayden, et al.
Publicado: (2021)

A Case of Dulaglutide-Induced Vaginal Bleed
por: Vaccaro, Christopher J, et al.
Publicado: (2023)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes
por: Valentine, William, et al.
Publicado: (2022)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States
por: Mody, Reema, et al.
Publicado: (2019)

Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
por: Pantalone, Kevin M., et al.
Publicado: (2018)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson, Angela M, et al.
Publicado: (2016)

An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption
por: Kyriakos, Georgios, et al.
Publicado: (2022)

Correction to Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
por: Wang, Rijun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4v6gjok7vskgs7qm91gmcjc7e8